Our Research

All in at every level

Much goes in to creating treatments and cures for Rett syndrome. IRSF’s investments have already produced game-changing discoveries and built essential treatment development infrastructure. Our leadership and support direct Rett research along a path to treatment and cures for all individuals with Rett.

Our strategy

IRSF’s Scientific Strategy consists of three guiding pillars that cover Rett research at every level:


Critical research
– Critical research addresses gaps in researchers’ knowledge of Rett syndrome, including MECP2 and other targets that give rise to the pathology of Rett. It equips researchers with the information they need to devise new ways to treat Rett and improve upon existing ones.



Pipeline development
– The Rett treatment development pipeline represents the assessments potential new treatments undergo to prepare for testing in clinical trials. IRSF works to improve the pipeline while helping companies developing Rett treatments to navigate it.



Clinical trials
– IRSF supports Rett clinical trials through facilitating communication and connection among the clinical trial stakeholders: Rett families, physicians, the FDA, and trial sponsors. At the same time, it invests in the infrastructure necessary for successful clinical trials such as Rett registries and research onoutcomes measures.

A FIRST FOR RETT: FDA approves Trofinetide for the treatment of Rett syndrome!
It’s Giving Tuesday - Go ALL IN for Rett!

A FIRST FOR RETT: FDA approves Trofinetide for the treatment of Rett syndrome!